The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20260767: Eli Lilly and Company; Ventyx Biosciences, Inc.
20260771: American Water Works Company, Inc.; IIF US Holdings 2 LP
20260775: New Mountain Partners VI, L.P.; New Mountain Partners VI Aggregator, L.P.
20260776: New Mountain Partners VI Aggregator, L.P.; New Mountain Partners VI, L.P.
20260784: Rite-Hite Holding Corporation Voting Trust; Randall L. Johnson
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.